Member Info for share12345

nt to buy
nice tree shake

about to take 74

100%
nice

looking good

re rate

here we go

gap up
coming

news maybe inbound

low free float

this done 600% last time
hold on

ten trades up 20%
wow

https://youtu.be/Y2LH4ugMCnU

write up from PRO ACTIVE just now'' sound good, I will post what is relevant to us''

"Today, the world needs big solutions to solve giant societal environmental problems. This joint venture is the most efficient route to deliver our world leading water technologies throughout the 23 provinces of China”, DeepVerge chief executive Gerard Brandon said in a statement.

“A joint venture with a division of one of the world's largest natural resource groups can meet the growing demand for manufacturing and assembly of existing Microtox and Microtrace equipment for environmental monitoring across the rest of the world, that is struggling to manage a global health pandemic. By partnering with China Resources we can futureproof DeepVerge as a leading innovator of smart environmental platforms with AI, equipment/devices and network management software capability", he added.

on bbc news now

Significant Shareholder % Held
Unicorn Asset Management 12.34
Jarvis Investment Management 11.83
ISPartners Investment Solutions 9.69
Hargreaves Lansdown Asset Management 9.53
Premier Miton Investors 7.93
Interative Investor 4.18
Intuitive Investments Group 4.11
Directors & Related Holdings 3.66
M D Barnard & Co 3.58

sorry wrong broad

Well, there is an opportunity that the masses haven’t cottoned onto yet.

Microsaic has some very interesting technology as it specialises in mass spectrometry. Confused? I can sympathise: ‘What the hell is that?’ was my reaction when I first came across the term ‘mass spectrometry’. That may be part of the reason many private investors have ignored it.

Allow me to explain… Mass spectrometers are designed to improve the efficiency of chemical and biological workflows. Specific applications of mass spectrometry include drug testing and discovery, food contamination detection, pesticide residue analysis, isotope ratio determination, protein identification, and carbon dating.

A recent agreement with DeepVerge enables Microsaic’s contamination detection equipment and services to be sold by DeepVerge’s sales network, as well as its marketing and distribution channels in the laboratory, chemical, biochemical, biofuel and biodegradable plastic and waste-water treatment industries.

Still, the development that really has me excited is the collaboration with DeepVerge to accelerate the development of the MicrotoxBT breathalyser. This ground-breaking device combines miniaturised mass spectrometry with DeepVerge’s AI data analytics to detect spike proteins of the COVID-19 virus, SARS-CoV-2, on a person’s breath. Resulting in fast, reliable, and efficient test results of the population at the point-of-need.

According to Microsaic, this platform has the potential to quickly enable GP clinics to refer serious conditions, by using biomarker binding agents capable of detecting up to 40 diseases on the human breath, including:

Cancer
Neurodegenerative conditions
Respiratory illnesses
Metabolic conditions

Well, there is an opportunity that the masses haven’t cottoned onto yet.

Microsaic has some very interesting technology as it specialises in mass spectrometry. Confused? I can sympathise: ‘What the hell is that?’ was my reaction when I first came across the term ‘mass spectrometry’. That may be part of the reason many private investors have ignored it.

Allow me to explain… Mass spectrometers are designed to improve the efficiency of chemical and biological workflows. Specific applications of mass spectrometry include drug testing and discovery, food contamination detection, pesticide residue analysis, isotope ratio determination, protein identification, and carbon dating.

A recent agreement with DeepVerge enables Microsaic’s contamination detection equipment and services to be sold by DeepVerge’s sales network, as well as its marketing and distribution channels in the laboratory, chemical, biochemical, biofuel and biodegradable plastic and waste-water treatment industries.

Still, the development that really has me excited is the collaboration with DeepVerge to accelerate the development of the MicrotoxBT breathalyser. This ground-breaking device combines miniaturised mass spectrometry with DeepVerge’s AI data analytics to detect spike proteins of the COVID-19 virus, SARS-CoV-2, on a person’s breath. Resulting in fast, reliable, and efficient test results of the population at the point-of-need.

According to Microsaic, this platform has the potential to quickly enable GP clinics to refer serious conditions, by using biomarker binding agents capable of detecting up to 40 diseases on the human breath, including:

Cancer
Neurodegenerative conditions
Respiratory illnesses
Metabolic conditions

it look like it is all going to kick of soon, with DVRG RNS out at the same time
that china JV is on for the microtox

HUGE NEWS FOR BOTH CO

GLA

DeepVerge will introduce Artificial Intelligence ("AI") data analytics to Microsaic's existing MS data capture capabilities to fast track the MicrotoxBT breathalyser, currently used for detecting the Spike Protein of the COVID-19 virus, SARS-CoV-2, to being able to deliver a "Point of Care" diagnostic solution at the GP's clinic. With biomarker binding agents capable of detecting up to 40 diseases on the human breath, many of which include types of cancer, neurodegenerative, respiratory and metabolic conditions, it has the potential to enable swift referral for serious conditions and at the same time reduce unnecessary doctor-to-hospital referrals and needless over-prescription of antibiotics, significantly lowering healthcare costs.